Because this payment demonstration operates outside coverage under a Part D plan, the $50 copayment toward these medications will not count toward a participating beneficiarys Part D deductible or the $2,100 out-of-pocket maximum in 2026 (increasing to $2,400 in 2027), and copayments will stay consistent at $50 per month, regardless of the Part D benefit phase a beneficiary is in when they fill the prescription
Xu Y, Jin X, Ping Q, Cheng J, Sun M, Cao F, You W, Yuan D
According to FDA prescribing information, nausea occurs in approximately 15-44% of patients depending on the specific agent and dose, with vomiting, diarrhea, constipation, and abdominal pain also frequently reported
Retatrutide has not received marketing authorisation from the MHRA and is not approved for clinical use in the UK